148 related articles for article (PubMed ID: 34294525)
1. Treatment and outcomes of hepatocellular carcinoma in patients with Sickle cell disease: a population-based study in the U.S.
Barbetta A; Goldbeck C; Lim A; Martin SP; Kahn JA; Sheikh MR; Emamaullee J
HPB (Oxford); 2022 Feb; 24(2):234-243. PubMed ID: 34294525
[TBL] [Abstract][Full Text] [Related]
2. Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States.
Davila JA; Duan Z; McGlynn KA; El-Serag HB
J Clin Gastroenterol; 2012 Jan; 46(1):71-7. PubMed ID: 22157221
[TBL] [Abstract][Full Text] [Related]
3. Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis.
Kim DS; Lim TS; Jeon MY; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Baatarkhuu O; Kim SU
Dig Dis Sci; 2019 Dec; 64(12):3660-3668. PubMed ID: 31187326
[TBL] [Abstract][Full Text] [Related]
4. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study.
El-Serag HB; Siegel AB; Davila JA; Shaib YH; Cayton-Woody M; McBride R; McGlynn KA
J Hepatol; 2006 Jan; 44(1):158-66. PubMed ID: 16290309
[TBL] [Abstract][Full Text] [Related]
5. A SEER Database Analysis of the Survival Advantage of Transarterial Chemoembolization for Hepatocellular Carcinoma: An Underutilized Therapy.
Gray SH; White JA; Li P; Kilgore ML; Redden DT; Abdel Aal AK; Simpson HN; McGuire B; Eckhoff DE; Dubay DA
J Vasc Interv Radiol; 2017 Feb; 28(2):231-237.e2. PubMed ID: 27939085
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Initial Transarterial Chemoembolization for Hepatocellular Carcinoma Among Medicare Beneficiaries.
Sanoff HK; Chang Y; Stavas JM; Stürmer T; Lund J
J Natl Compr Canc Netw; 2015 Sep; 13(9):1102-10. PubMed ID: 26358794
[TBL] [Abstract][Full Text] [Related]
7. Earlier presentation and application of curative treatments in hepatocellular carcinoma.
Ulahannan SV; Duffy AG; McNeel TS; Kish JK; Dickie LA; Rahma OE; McGlynn KA; Greten TF; Altekruse SF
Hepatology; 2014 Nov; 60(5):1637-44. PubMed ID: 24996116
[TBL] [Abstract][Full Text] [Related]
8. Preoperative transcatheter arterial chemoembolization for surgical resection of huge hepatocellular carcinoma (≥ 10 cm): a multicenter propensity matching analysis.
Li C; Wang MD; Lu L; Wu H; Yu JJ; Zhang WG; Pawlik TM; Zhang YM; Zhou YH; Gu WM; Wang H; Chen TH; Han J; Xing H; Li ZL; Lau WY; Wu MC; Shen F; Yang T
Hepatol Int; 2019 Nov; 13(6):736-747. PubMed ID: 31486964
[TBL] [Abstract][Full Text] [Related]
9. Liver Transplantation in Patients with Sickle Cell Disease in the United States.
Hogen R; Kim M; Lee Y; Lo M; Kaur N; Kahn J; Chopra S; Qazi Y; Sedra A; Kim J; O'Brien L; Genyk Y; Sher L; Emamaullee J
J Surg Res; 2020 Nov; 255():23-32. PubMed ID: 32540577
[TBL] [Abstract][Full Text] [Related]
10. Factors Associated With Complete Pathologic Necrosis of Hepatocellular Carcinoma on Explant Evaluation After Locoregional Therapy: A National Analysis Using the UNOS Database.
Sarwar A; Bonder A; Hassan L; Malik MS; Novack V; Curry M; Ahmed M
AJR Am J Roentgenol; 2023 May; 220(5):727-735. PubMed ID: 36475810
[No Abstract] [Full Text] [Related]
11. Comparison of hepatic resection and transarterial chemoembolization for UICC stage T3 hepatocellular carcinoma: a propensity score matching study.
Zhong C; Zhang YF; Huang JH; Xiong CM; Wang ZY; Chen QL; Guo RP
BMC Cancer; 2018 Jun; 18(1):643. PubMed ID: 29879928
[TBL] [Abstract][Full Text] [Related]
12. Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare.
Zhang X; El-Serag HB; Thrift AP
Cancer Causes Control; 2021 Apr; 32(4):317-325. PubMed ID: 33394207
[TBL] [Abstract][Full Text] [Related]
13. Early stage hepatocellular carcinoma in the elderly: A SEER database analysis.
Oweira H; Petrausch U; Helbling D; Schmidt J; Mannhart M; Mehrabi A; Schöb O; Giryes A; Abdel-Rahman O
J Geriatr Oncol; 2017 Jul; 8(4):277-283. PubMed ID: 28389117
[TBL] [Abstract][Full Text] [Related]
14. Healthcare Costs for Medicare Patients With Hepatocellular Carcinoma in the United States.
Karim MA; Ramezani M; Leroux T; Kum HC; Singal AG
Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2327-2337.e9. PubMed ID: 36435358
[TBL] [Abstract][Full Text] [Related]
15. Impact of preoperative TACE on incidences of microvascular invasion and long-term post-hepatectomy survival in hepatocellular carcinoma patients: A propensity score matching analysis.
Yang Y; Lin K; Liu L; Qian Y; Yang Y; Yuan S; Zhu P; Huang J; Liu F; Gu F; Fu S; Jiang B; Liu H; Pan Z; Lau WY; Zhou W
Cancer Med; 2021 Mar; 10(6):2100-2111. PubMed ID: 33650288
[TBL] [Abstract][Full Text] [Related]
16. Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.
Patel MV; Davies H; Williams AO; Bromilow T; Baker H; Mealing S; Holmes H; Anderson N; Ahmed O
J Med Econ; 2023; 26(1):1061-1071. PubMed ID: 37632520
[TBL] [Abstract][Full Text] [Related]
17. Patterns of Care and Outcomes of Definitive External Beam Radiotherapy and Radioembolization for Localized Hepatocellular Carcinoma: A Propensity Score-adjusted Analysis.
Bitterman DS; Sanford NN; Niemierko A; Mahal BA; Qadan M; Ganguli S; Blaszkowsky LS; Zhu AX; Hong TS; Devlin PM; Goyal L; Wo JY
Am J Clin Oncol; 2019 Jul; 42(7):564-572. PubMed ID: 31166209
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.
Lee YT; Wang JJ; Luu M; Noureddin M; Nissen NN; Patel TC; Roberts LR; Singal AG; Gores GJ; Yang JD
Hepatology; 2021 Nov; 74(5):2622-2632. PubMed ID: 34114675
[TBL] [Abstract][Full Text] [Related]
19. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease.
Wong CR; Njei B; Nguyen MH; Nguyen A; Lim JK
Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1061-1069. PubMed ID: 28960360
[TBL] [Abstract][Full Text] [Related]
20. Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database.
Uhlig J; Sellers CM; Stein SM; Kim HS
Eur Radiol; 2019 May; 29(5):2679-2689. PubMed ID: 30560364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
